Sydney

Recce Pharmaceuticals Announces Update on Phase I/II Clinical Trial for the Treatment of Burn Wound Infections

Retrieved on: 
Tuesday, December 7, 2021
Pseudomonas, Synthetic, RCE, Company, Trial, GLOBE, Recce, Patient, Data, Biofilm, Safety, Bacteria, Burn, Death, Wound healing, Virus, Fiona Stanley Hospital, Proteus vulgaris, Gram-negative bacteria, Sensation, ASX, Staphylococcus lugdunensis, Degenerative disease, Infection, GAIN, Proteus mirabilis, Clinical trial, Gram, FDA, Morganella morganii, Update, Sepsis, Genetically modified bacteria, FSE, Pew, Vaccine, Pharmaceutical industry

SYDNEY, Australia, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its Phase I/II clinical trial for the treatment of burn wound infections.The West Australian Health department sponsored clinical trial at Fiona Stanley Hospital is assessing the safety and efficacy of RECCE® 327 (R327) in patients with infected burn wounds under the Trial ID ACTRN12621000412831.

Key Points: 
  • The West Australian Health department sponsored clinical trial at Fiona Stanley Hospital is assessing the safety and efficacy of RECCE 327 (R327) in patients with infected burn wounds under the Trial ID ACTRN12621000412831.
  • We are highly encouraged by the initial success of R327 in this topical Phase I/II trial, said Dr. Ed Raby, Study Investigator.
  • Patients with burn wounds often suffer severe bacterial infections that are painful, prevent wound healing, and can even result in death if not properly treated.
  • James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, We are pleased with the progress of our lead compound, R327, in patients harboring serious burn wound infections.

Cryptosphere NFT Completes Sold-Out NFT Pre-Sale

Retrieved on: 
Thursday, December 2, 2021
Non-fungible token, NFT, Augmented reality, Sale, GLOBE, AR, Immersion, ETH, Cryptocurrency

Sydney, Australia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire ) Cryptosphere NFT , an up-and-coming NFT, and gaming platform has just concluded its pre-sale.

Key Points: 
  • Sydney, Australia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- (via Blockchain Wire ) Cryptosphere NFT , an up-and-coming NFT, and gaming platform has just concluded its pre-sale.
  • Additionally, Cryptosphere NFT is preparing for the imminent public sale.
  • Cryptosphere NFT uses transparent features and trustability to build a loyal community around it.
  • Cryptosphere NFT is a new presence in the gaming and NFT market.

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

Retrieved on: 
Thursday, December 2, 2021
Patient, Research, Immutep, Safety, Technology, LAG-3, ASX, Autoimmune disease, Cancer, Australian Securities Exchange, Carboplatin, Institute, APC, GLOBE, Antibody, Immunotherapy, Calendar, Infection, NASDAQ, IMM, Pharmaceutical industry, Vaccine

We are very pleased with the safety of the triple combination so far and all patients are still participating in the study.

Key Points: 
  • We are very pleased with the safety of the triple combination so far and all patients are still participating in the study.
  • This is important as it is the first time patients have received a triple combination therapy with efti.
  • INSIGHT-003 is evaluating a triple combination therapy consisting of efti in conjunction with an existingapproved standard of care combination of chemotherapy and anti-PD-1 therapy.
  • The study is evaluating a triple combination therapy consisting of efti in conjunction with an existing approved standard of care combination of chemotherapy (carboplatin) and anti-PD-1 therapy.

UbuntuToken Community Presale Happening on Pinksale - December 4, 2021

Retrieved on: 
Wednesday, December 1, 2021
Ethereum, Polygon, Organic, Non-fungible token, Sale, Social media, Cryptocurrency

UbuntuToken is a decentralized global cryptocurrency exchange platform that leverages Blockchain in order to support charities.

Key Points: 
  • UbuntuToken is a decentralized global cryptocurrency exchange platform that leverages Blockchain in order to support charities.
  • The UbuntuToken platform uses a combination of the 3 most common blockchain networks - Ethereum, Polygon, and Binance Smart Chain.
  • Beyond the presale, the UbuntuToken project is also offering a $UBUT airdrop for participating users.
  • For more information on the community pre-sale of UbuntuTokens or any other aspect of the UbuntuToken project, please contact our support team at [email protected].

Doxxed Santa is Bringing Gifts to the Crypto Community this Holiday Season

Retrieved on: 
Friday, November 26, 2021
Trust, Rest, Moon, GLOBE, Marketing, KYC, Social media, Cryptocurrency, Amusement park

Their marketing wallet is committed to marketing with an assurance that it will keep shooting for the moon even after the holiday season.

Key Points: 
  • Their marketing wallet is committed to marketing with an assurance that it will keep shooting for the moon even after the holiday season.
  • It is your chance to grab and hodl Doxxed Santa.
  • Doxxed Santa will soon launch the presale on 29th on Unicrypt.
  • Doxxed Santa is here to give you all gifts of joy on its journey to more development.

Amcor, Coles, iQ Renew, Licella, LyondellBasell and Nestlé Findings Support Australian-First Advanced Recycling Plant

Retrieved on: 
Monday, November 22, 2021
Policy, Government, Industry, Recycling, World, Food packaging, Amcor, Plastic, LyondellBasell, GLOBE, CO2, HTL

Advanced recycling allows soft plastic waste, like confectionery wrappers and bread bags, to be turned back into oil, then made into new food-grade packaging in Australia.

Key Points: 
  • Advanced recycling allows soft plastic waste, like confectionery wrappers and bread bags, to be turned back into oil, then made into new food-grade packaging in Australia.
  • It is an opportunity to establish Victoria, and Australia, as a leader in this emerging new industry.
  • The proposed advanced recycling facility would use innovative Australian technology called Cat-HTR (Catalytic Hydrothermal Reactor), a form of hydrothermal liquefaction technology developed by Licella.
  • HTL is the 'next-generation' of advanced recycling, chemically transforming low value feedstocks into oil, which can be refined to high value fuels and chemicals.

TheraCann Australia Congratulates Ivory Medical (PVT) Ltd., on its Successful Groundbreaking Event

Retrieved on: 
Wednesday, November 17, 2021
Benchmark, One Solution, GMP, Biomass, Technology, ATG, Compliance, Solution, Plant, 2019 Allied Steel Buildings 200, PVT, ISO, APDD Pty Ltd, CO2, Terpene, Emergency evacuation, Maintenance, OS2, Cannabinoid, Medical device, Perfume

Ltd. (TheraCann Australia), a fully owned subsidiary of TheraCann International Benchmark Corp. (TheraCann International), wishes to congratulate Ivory Medical (PVT) Ltd. (Ivory Medical), on its successful groundbreaking event and the commencement of its site preparation.

Key Points: 
  • Ltd. (TheraCann Australia), a fully owned subsidiary of TheraCann International Benchmark Corp. (TheraCann International), wishes to congratulate Ivory Medical (PVT) Ltd. (Ivory Medical), on its successful groundbreaking event and the commencement of its site preparation.
  • Ivory Medical has commissioned this unique facility to provide industrial scale, EU GMP compliant, configurable white label medical cannabis products to foreign markets.
  • Under wholesale white label contracts, Ivory Medical will produce, process, and package medical cannabis products to meet client requirements.
  • TheraCann Australia has been contracted by Ivory Medical, under a 5-year managed services agreement, to provide technical and operational support for this facility.

Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study of LAG-3 Therapy, Eftilagimod Alpha

Retrieved on: 
Friday, November 19, 2021
Patient, Part, NSCLC, Immutep, PD-L1, Technology, LAG-3, Merck, Head, Autoimmune disease, Large-cell lung carcinoma, Cancer, Australian Securities Exchange, HNSCC, Neck, Pembrolizumab, APC, Antibody, COVID-19, Merck & Co., Infection, NASDAQ, IMM, Pharmaceutical industry, Health insurance, Palladium, Vaccine

The study is evaluating the combination of eftilagimod alpha (efti) with MSDs KEYTRUDA (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.

Key Points: 
  • The study is evaluating the combination of eftilagimod alpha (efti) with MSDs KEYTRUDA (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line.
  • The trial is a Phase II, Simons two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in study centres across Australia, Europe, and the US.
  • Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
  • Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.